menu
    • menu

    Company profile for Talphera

    NEW Drugs in Dev: 3
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Talphera, Inc. is a specialized pharmaceutical company dedicated to advancing and commercializing innovative therapies tailored for use in medically supervised environments. The company's flagship product, Niyad™, is a lyophilized formulation of nafamostat, currently undergoing investigation under an investigational device exemption (IDE). Niyad™ is specifically being studied as an anticoagulant for the extracorporeal circ...
    Talphera, Inc. is a specialized pharmaceutical company dedicated to advancing and commercializing innovative therapies tailored for use in medically supervised environments. The company's flagship product, Niyad™, is a lyophilized formulation of nafamostat, currently undergoing investigation under an investigational device exemption (IDE). Niyad™ is specifically being studied as an anticoagulant for the extracorporeal circuit and has received Breakthrough Device Designation status from the FDA. In addition, Talphera is actively involved in the development of two pre-filled syringes, Fedsyra™ and PFS-02.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TalpheraUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Mateo, CA 94404
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://talphera.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/acelrx-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arvo

    Arvo

    Not Confirmed

    envelop Contact Supplier

    Arvo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Talphera To Present Two Abstracts At AKI & CRRT 2026
    Talphera To Present Two Abstracts At AKI & CRRT 2026

    25 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/talphera-announces-two-abstracts-accepted-for-presentation-at-aki--crrt-2026-302724115.html

    PR NEWSWIRE
    25 Mar 2026
    Share Share
    Talphera Unveils 2025 Financial Results & Corporate Update
    Talphera Unveils 2025 Financial Results & Corporate Update

    23 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/talphera-announces-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update-302721514.html

    PR NEWSWIRE
    23 Mar 2026
    Share Share
    Talphera to Host Virtual Niyad CRRT Event on March 23, 2026
    Talphera to Host Virtual Niyad CRRT Event on March 23, 2026

    18 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/talphera-to-host-virtual-investor--analyst-event-to-discuss-niyad-for-use-in-continuous-renal-replacement-therapy-crrt-on-march-23-2026-302717591.html

    PR NEWSWIRE
    18 Mar 2026
    Share Share
    Talphera Reaches 50% Enrollment Milestone In NEPHRO-CRRT Trial
    Talphera Reaches 50% Enrollment Milestone In NEPHRO-CRRT Trial

    02 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/talphera-announces-50-enrollment-milestone-in-ongoing-nephro-crrt-registrational-trial-302700601.html

    PR NEWSWIRE
    02 Mar 2026
    Share Share
    Talphera Reveals Q3 2025 Financials & Corporate Updates
    Talphera Reveals Q3 2025 Financials & Corporate Updates

    13 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/talphera-announces-third-quarter-2025-financial-results-and-provides-corporate-update-302613486.html

    PR NEWSWIRE
    13 Nov 2025
    Share Share
    Talphera To Host Q3 Financial Results Call On Nov 12, 2025
    Talphera To Host Q3 Financial Results Call On Nov 12, 2025

    05 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/talphera-to-host-third-quarter-financial-results-and-corporate-update-call-and-webcast-on-wednesday-november-12-2025-302604832.html

    PR NEWSWIRE
    05 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search